You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Abbvie to continue manufacturing component for lymphoma drug
State Of Indonesian Online Video: Subscription
Virtual Multichannel Revenues Projected To Soar In Next Five Years
Street Talk Episode 45 - Fed Moving From Rate Hikes To Lower For Longer
Consumer Engagement Remains Challenging For OTT Players In Asia
Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.
The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.
Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.